Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 7:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Non-Investigational Surgical Resection Clear all
Recruiting Phase 2 Interventional

Embryonal Tumor With Multilayered Rosettes

NCT06861244
View directory record Official record
Conditions
Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos
Interventions
Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection, Temozolomide, Tumor Tissue Sample, Blood Sample, Cerebrospinal Fluid (CSF) Sample
Radiation · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 17, 2026, 7:53 AM EDT
Terminated Phase 3 Interventional

Stage IV Surgery Versus Best Medical Therapy

NCT01013623
View directory record Official record
Conditions
Stage IV Resectable Melanoma
Interventions
Surgery, Surgery plus 2 adjuvant doses of BCG, best medical therapy
Procedure · Other
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Sep 17, 2026, 7:53 AM EDT
Completed Not applicable Interventional Results available

Pancreas Resection With and Without Drains

NCT01441492
View directory record Official record
Conditions
Pancreas Tumor, Pancreatitis
Interventions
No Drains, Drains
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
12
States / cities
Gainesville, Florida • Tampa, Florida • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Sep 17, 2026, 7:53 AM EDT
Active, not recruiting Phase 2 Interventional

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

NCT03856658
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Liver Metastases
Interventions
Floxuridine (FUDR), Hepatic Artery Infusion Pump, Heparinized Saline
Drug · Device
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 17, 2026, 7:53 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

NCT07154706
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Taletrectinib, Placebo
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 17, 2026, 7:53 AM EDT
Recruiting Phase 3 Interventional

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

NCT05568719
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Testing of hepatic AAV Vector integration
Diagnostic Test
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
14
States / cities
Rancho Cordova, California • Sacramento, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 17, 2026, 7:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

NCT02010567
View directory record Official record
Conditions
Rectal Cancer
Interventions
CRLX101, Capecitabine, Radiotherapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
6
States / cities
Denver, Colorado • Indianapolis, Indiana • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 17, 2026, 7:53 AM EDT
Completed No phase listed Observational

A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer

NCT04951154
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Bronchoscopic Biopsy, Blood Sample
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 17, 2026, 7:53 AM EDT
Completed Early Phase 1 Interventional

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

NCT01980823
View directory record Official record
Conditions
Breast Cancer, Breast Tumors, Cancer of Breast
Interventions
Metformin, Atorvastatin, Breast surgery
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 17, 2026, 7:53 AM EDT
Suspended Phase 2 Interventional

Methimazole in Patients With Progressive Glioblastoma

NCT05607407
View directory record Official record
Conditions
Glioblastoma, Glioma
Interventions
Methimazole, Recurrent Glioblastoma Surgical Resection, Pharmacodynamic Assays
Drug · Procedure · Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 17, 2026, 7:53 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Histologic Evaluation of Tissue Following Lutronic System Exposure

NCT04207047
View directory record Official record
Conditions
Abdominoplasty
Interventions
Genius, eC02, PicoPlus, LaseMD, LaseMD Flex
Device
Lead sponsor
CynosureLutronic
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Billerica, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Sep 17, 2026, 7:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metabolomic Analysis of Lung Cancer

NCT00263731
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung
Interventions
13-C-glucose
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 17, 2026, 7:53 AM EDT
Completed Early Phase 1 Interventional

Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

NCT02452216
View directory record Official record
Conditions
Brain Injury, Central Nervous System Degenerative Disorder, Central Nervous System Infectious Disorder, Central Nervous System Vascular Malformation, Hemorrhagic Cerebrovascular Accident, Ischemic Cerebrovascular Accident, Primary Brain Neoplasm, Brain Cancer, Brain Tumors
Interventions
Ferumoxytol, Tissue Analysis, Magnetic Resonance Imaging
Drug · Other · Procedure
Lead sponsor
Michael Iv
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 17, 2026, 7:53 AM EDT
Recruiting Early Phase 1 Interventional

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

NCT05553782
View directory record Official record
Conditions
Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland, Squamous Cell Carcinoma of Head and Neck, Head and Neck Cancer
Interventions
Implantable Microdevice (IMD)
Combination Product
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 17, 2026, 7:53 AM EDT
Terminated Not applicable Interventional Results available

Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound

NCT02218242
View directory record Official record
Conditions
Lung Cancer
Interventions
Intraoperative ultrasound
Device
Lead sponsor
Joel Thompson, PhD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 17, 2026, 7:53 AM EDT
Recruiting Phase 2 Interventional

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

NCT05726292
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 17, 2026, 7:53 AM EDT
Withdrawn Phase 2 Interventional

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

NCT03005639
View directory record Official record
Conditions
Stage IIIB-C Melanoma
Interventions
Vemurafenib and Cobimetinib
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 17, 2026, 7:53 AM EDT
Recruiting Phase 2 Interventional

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

NCT07126158
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Cancer of the Pancreas, Pancreas Cancer, Pancreatic Cancer
Interventions
Stereotactic body radiotherapy, Defactinib, Avutometinib
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 17, 2026, 7:53 AM EDT
Recruiting Phase 1 Interventional

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

NCT06186401
View directory record Official record
Conditions
EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical resection
Biological · Drug · Procedure
Lead sponsor
Hideho Okada, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 17, 2026, 7:53 AM EDT
Not listed Not applicable Interventional

EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO Trial)

NCT05151172
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
endovascular thrombectomy (EVT), Standarad medical care
Device · Other
Lead sponsor
Dr. Michael D Hill
Other
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Little Rock, Arkansas • San Francisco, California • Torrance, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Sep 17, 2026, 7:53 AM EDT
Completed Not applicable Interventional Results available

Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer

NCT02318095
View directory record Official record
Conditions
Resectable Pancreatic Cancers
Interventions
Gemcitabine/nab-Paclitaxel, Radiation therapy, Sugical resection, Adjuvant chemotheapy
Drug · Radiation · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 17, 2026, 7:53 AM EDT
Terminated Not applicable Interventional Results available

Oxygen Measurements in Subcutaneous Tumors by EPR Oximetry Using OxyChip

NCT02706197
View directory record Official record
Conditions
Neoplasms, Benign, Neoplasms, Malignant
Interventions
OxyChip
Device
Lead sponsor
Periannan Kuppusamy
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 17, 2026, 7:53 AM EDT
Completed No phase listed Observational Results available

Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

NCT05105100
View directory record Official record
Conditions
Melanoma, Advanced Melanoma
Interventions
Biopsy, Biospecimen Collection
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 17, 2026, 7:53 AM EDT
Completed Phase 2 Interventional Results available

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

NCT05549505
View directory record Official record
Conditions
Breast Cancer
Interventions
ARV-471, Anastrozole, Surgical resection of breast tumor
Drug · Procedure
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 17, 2026, 7:53 AM EDT